Respiratory

Hemoptysis: massive vs nonmassive workup

Clinical Overview and When to Suspect Hemoptysis

— Nonmassive (mild/moderate): <100 mL/24 h; hemodynamically stable, no gas exchange compromise

— Massive (life-threatening): >100–600 mL/24 h OR any rate causing airway obstruction, hypoxemia, or hemodynamic instability. Modern definition emphasizes physiologic effect over absolute volume

— Bronchial arteries (~90% of massive bleeds): systemic pressure, high-flow, originate from aorta → catastrophic bleeding

— Pulmonary arteries (~5%): low pressure; think Rasmussen aneurysm (TB cavity), PA catheter injury

— Bronchopulmonary shunts: chronic inflammation (bronchiectasis, CF, aspergilloma)

— Smoker >40 with new hemoptysis → lung cancer until proven otherwise, even single episode

— Chronic productive cough + recurrent hemoptysis → bronchiectasis

— Hemoptysis + hematuria → pulmonary-renal syndrome (GPA, anti-GBM)

— Hemoptysis + pleuritic chest pain + risk factors → PE with infarction

— Travel/incarceration/HIV/immigrant → TB

Board pearl: Death in massive hemoptysis is from asphyxiation, not exsanguination — the alveoli flood faster than the patient bleeds out. This reframes the entire airway-first management strategy in CCS cases.

Definition: Expectoration of blood originating from the subglottic airways or lung parenchyma. Must be distinguished from pseudohemoptysis (nasopharyngeal/oral source) and hematemesis (GI source).

Volume-based classification (no universal threshold; use clinical impact):

Anatomy that drives the clinical urgency:

When to suspect a serious etiology (Step 3 outpatient lens):

Epidemiology pearl: Globally TB dominates; in US outpatient practice, bronchitis, bronchiectasis, and lung cancer are top three. Cryptogenic hemoptysis (no cause found) accounts for up to 20–30%.

Presentation Patterns and Key History

— Bright red, frothy, mixed with sputum → airway/parenchymal source (true hemoptysis)

— Coffee-ground, food particles, acidic → hematemesis

— Blood streaking from gums/posterior pharynx → pseudohemoptysis

— Purulent + blood-tinged → infectious bronchitis, pneumonia, lung abscess

— Teaspoons over days with URI → bronchitis (most common nonmassive cause)

— Cupfuls or filling a basin → massive; activate protocol immediately

— Recurrent small-volume bleeds in same patient → bronchiectasis, AVM, mycetoma, tumor

— Constitutional (weight loss, night sweats, fevers): TB, malignancy, vasculitis

— Hematuria, sinusitis, saddle nose: GPA

— Hemoptysis + dyspnea + heart murmur: mitral stenosis (rare but classic)

— Menstrual-synchronous hemoptysis (catamenial): thoracic endometriosis

— Recent immobilization, OCPs, malignancy, leg swelling: PE

— Anticoagulant/antiplatelet use, DOAC dosing, recent INR: drug-induced bleeding diathesis

— Cocaine/crack inhalation: alveolar hemorrhage

— Occupational silica, asbestos, pigeon exposure: parenchymal disease

Step 3 management: On any new hemoptysis encounter, document smoking pack-years, anticoagulation status, TB exposure, and prior chest imaging before deciding outpatient vs ED disposition. These four data points drive ~80% of triage decisions.

Characterize the blood itself:

Volume and tempo:

Targeted history — match to syndrome:

Past medical clues: prior TB, CF, transplant, sickle cell (acute chest), HIV (Kaposi, PCP, TB), prior radiation, recent bronchoscopy or PA catheter.

Medication reconciliation is mandatory at intake — bevacizumab, ibrutinib, anticoagulants, and antiplatelets dramatically alter both risk and management.

Physical Exam Findings and Hemodynamic Assessment

— RR >24, SpO₂ <90% on room air, accessory muscle use → impending respiratory failure

— Hypotension + tachycardia → significant volume loss or tension from clot

— Stridor or gurgling → upper airway clot; prepare for emergent intubation

— Focal crackles or bronchial breath sounds → likely bleeding lobe (helpful for positioning bleeding-side down to protect the good lung)

— Diffuse crackles + hypoxemia + dropping hemoglobin → diffuse alveolar hemorrhage (DAH)

— Wheezing localized to one area → endobronchial tumor or foreign body

— Loud P2, RV heave → pulmonary hypertension

— Opening snap, diastolic rumble → mitral stenosis

— S3, JVD, rales → CHF with pink frothy sputum (mimics hemoptysis)

— Saddle nose, septal perforation, oral ulcers: GPA

— Palpable purpura, mononeuritis multiplex: vasculitis (EGPA, MPA, GPA)

— Clubbing: bronchiectasis, lung cancer, ILD, CF

— Telangiectasias on lips/tongue: HHT (Osler-Weber-Rendu) → pulmonary AVM

— Cervical/supraclavicular lymphadenopathy: malignancy, TB

— Lower-extremity edema/asymmetry: DVT/PE

— Petechiae, ecchymoses: thrombocytopenia, DIC

Key distinction: A patient with rising respiratory rate but stable BP in massive hemoptysis is still critical — asphyxiation precedes shock. Do not be falsely reassured by a normal MAP while SpO₂ drifts down.

Airway, Breathing, Circulation first — hemoptysis exam begins with vitals, not auscultation.

Pulmonary exam — localize the bleed:

Cardiac exam:

Extrapulmonary clues — pattern recognition:

Quick bedside test: Have patient swish-and-spit; if blood persists from lower airway despite a clean oropharynx, source is subglottic.

Diagnostic Workup — Initial Labs and Imaging

— CBC with differential — anemia magnitude, leukocytosis (infection), eosinophilia (EGPA, ABPA)

— Coagulation panel: PT/INR, aPTT; add anti-Xa if on DOAC and bleeding

— Type and screen → type and crossmatch if massive

— BMP — uremia causes platelet dysfunction; baseline creatinine before contrast CT

— Urinalysis with microscopy — dysmorphic RBCs or RBC casts = pulmonary-renal syndrome until disproven

— ABG if SpO₂ <94% or distressed

— Troponin, BNP if cardiac etiology suspected

— ANCA (c-ANCA/PR3, p-ANCA/MPO), anti-GBM, ANA, complement (C3/C4), anti-dsDNA

— Order before initiating steroids if possible (won't change results, but documents pretreatment serology)

— Sputum Gram stain, bacterial culture, AFB smear ×3, mycobacterial culture, fungal culture, NAAT for TB if any risk factor

— HIV testing, galactomannan if immunocompromised

— CXR PA/lateral first — fast, identifies mass, cavity, infiltrate, effusion. Normal in ~30% of true hemoptysis — does not rule out malignancy

— CT chest with IV contrast (multidetector CTA) is the single most useful test: localizes bleed, defines bronchial arteries, identifies tumor/bronchiectasis/AVM/PE

— V/Q scan only if contrast contraindicated and PE suspected

CCS pearl: Order CT angiography of the chest rather than "CT chest with contrast" — the arterial-phase timing is essential for identifying bronchial artery hypertrophy and a bleeding source before interventional radiology consultation.

Universal initial labs (every hemoptysis patient with more than trivial bleeding):

Targeted serologies when vasculitis/autoimmune suspected:

Infectious workup:

Imaging — stepwise:

ECG: rule out atrial fibrillation (anticoagulation context), right heart strain (PE).

Diagnostic Workup — Advanced and Confirmatory Studies

— Flexible bronchoscopy: preferred for nonmassive hemoptysis with localized findings or persistent symptoms; allows BAL, biopsy, and washings

— Rigid bronchoscopy: preferred for massive hemoptysis — superior suction, ventilation, tamponade, and ability to place balloon blockers or apply argon/electrocautery

— Timing: early bronchoscopy (within 24–48 h) improves localization yield in active bleeding from ~50% to ~90%

— Progressively bloodier returns across sequential aliquots → diffuse alveolar hemorrhage (DAH)

— >20% hemosiderin-laden macrophages → DAH (acute or subacute)

— Positive AFB, fungal elements, malignant cytology → respective diagnosis

— HRCT (noncontrast thin-cut) — best for bronchiectasis, ILD, cavities, mycetoma ("air crescent sign")

— CT with delayed phase — AVM characterization, vascular malformations

— TTE for suspected mitral stenosis, pulmonary HTN, endocarditis with septic emboli

— TEE if endocarditis suspected and TTE nondiagnostic

— Now largely therapeutic (bronchial artery embolization, BAE) rather than purely diagnostic; performed by IR

— Reserved for confirmed/persistent bleeding where CTA has localized the source

— Endobronchial biopsy for visible lesions

— Transbronchial or CT-guided biopsy for parenchymal lesions

— Renal biopsy when pulmonary-renal syndrome suspected — often faster and safer than lung biopsy

Board pearl: In a patient with hemoptysis + hematuria + RBC casts + positive anti-GBM, the diagnosis is Goodpasture syndrome; do not wait for lung biopsy — initiate plasmapheresis + cyclophosphamide + steroids immediately and obtain renal biopsy for confirmation.

Bronchoscopy — when and what type:

BAL findings that clinch a diagnosis:

Cross-sectional imaging adjuncts:

Echocardiography:

Pulmonary angiography:

Tissue diagnosis:

Risk Stratification and First-Line Management Logic

— Massive criteria (any one): >100 mL/h or >500 mL/24 h, hemodynamic instability, hypoxemia, airway compromise → ICU + emergent intervention pathway

— Nonmassive: outpatient workup if stable, no anticoagulation, no high-risk features, reliable follow-up

— 1. Airway: position patient bleeding-side down (lateral decubitus) to protect the good lung; suction; supplemental O₂

— 2. Intubation: use a large-bore (≥8.0) single-lumen ETT to permit therapeutic bronchoscopy; selective mainstem intubation of the nonbleeding lung if needed

— 3. Reverse coagulopathy: vitamin K, PCC for warfarin; idarucizumab (dabigatran); andexanet/PCC (Xa inhibitors); platelets if <50K; hold antiplatelets

— 4. IV access: two large-bore IVs, crystalloid, transfuse for Hb <7 (or <8 with cardiac disease)

— 5. Localize: urgent CTA chest if stable enough; otherwise straight to bronchoscopy

— 6. Definitive control: bronchial artery embolization (BAE) is first-line; surgery if BAE fails or bleeding source unresectable medically

— Smoker >40 or any risk factor → CT chest + bronchoscopy referral even if CXR normal

— Young nonsmoker with URI symptoms and minor blood streaking → observation, treat bronchitis, repeat CXR in 4–6 weeks, return precautions

— Persistent or recurrent hemoptysis regardless of demographics → CT + bronchoscopy

Step 3 management: Even a single episode of hemoptysis in a smoker over 40 mandates outpatient CT chest + pulmonology referral for bronchoscopy — a normal CXR is insufficient to close the workup. This is a frequently tested ambulatory decision point.

The first fork in the road: massive vs nonmassive.

Massive hemoptysis algorithm — sequential priorities:

Nonmassive outpatient pathway:

Antitussives (codeine, dextromethorphan): controversial — may reduce trauma but risk clot retention; generally avoid in massive bleeding.

Pharmacotherapy — First-Line Regimens

— Warfarin: IV vitamin K 5–10 mg + 4-factor PCC (Kcentra) dosed by INR and weight; FFP only if PCC unavailable

— Dabigatran: idarucizumab 5 g IV

— Apixaban/rivaroxaban/edoxaban: andexanet alfa (if available and life-threatening); otherwise 4-factor PCC 50 U/kg

— Heparin: protamine 1 mg per 100 U heparin given in last 2–3 h

— Antiplatelets: platelet transfusion of unclear benefit; consider in life-threatening bleed on dual antiplatelet therapy

— Nebulized TXA 500 mg in 5 mL saline TID-QID reduces bleeding in nonmassive hemoptysis (small RCTs); inexpensive, low-risk adjunct

— IV TXA 1 g may be used but evidence is weaker; avoid in DIC or active thromboembolism

— TB: RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol) after AFB/NAAT confirmation; respiratory isolation before treatment starts

— Bacterial pneumonia/bronchitis: guideline-directed antibiotics; if blood-streaked sputum from bronchitis without pneumonia, antibiotics generally not indicated

— Aspergilloma/invasive aspergillosis: voriconazole first-line for invasive; aspergilloma often requires resection rather than antifungal alone

— ABPA: oral prednisone + itraconazole

— Vasculitis (GPA, MPA, EGPA): high-dose IV methylprednisolone 1 g daily ×3 → oral prednisone taper, plus rituximab or cyclophosphamide for induction

— Anti-GBM (Goodpasture): plasmapheresis + cyclophosphamide + corticosteroids

— CF/bronchiectasis flare: treat infection, airway clearance, consider chronic suppressive antibiotics

Board pearl: Nebulized TXA is now a high-yield first-line adjunct for nonmassive hemoptysis and increasingly appears in exam vignettes — a low-cost, well-tolerated intervention before invasive measures.

Reversal of anticoagulation (cornerstone of initial pharmacotherapy):

Tranexamic acid (TXA):

Etiology-directed pharmacotherapy:

Avoid NSAIDs and resume baseline antiplatelets/anticoagulants only after definitive bleeding control and individualized risk-benefit reassessment.

Procedures and Invasive Management

— First-line definitive therapy for massive hemoptysis and recurrent nonmassive hemoptysis refractory to medical management

— Immediate success rate 85–95%; rebleeding rate 10–30% at 1 year (highest in aspergilloma, TB sequelae, advanced bronchiectasis)

— Major complication: spinal cord ischemia (~1%) from inadvertent anterior spinal artery embolization — interventional radiologist performs spinal angiography to identify before embolization

— Other complications: chest pain (transient, common), dysphagia, bronchial necrosis (rare)

— Endobronchial balloon tamponade (Fogarty or specialized blocker) — buys time before BAE/surgery

— Cold saline lavage, topical epinephrine (1:20,000), topical TXA

— Argon plasma coagulation, electrocautery, laser, cryotherapy for endobronchial tumors

— Endobronchial stents rarely used for bleeding control directly

— Indications: BAE failure, persistent bleeding from a localized resectable source, aspergilloma in fit patient, trauma, AVM not amenable to embolization, iatrogenic PA rupture

— Avoid emergent surgery during active bleeding if possible — mortality 25–50% vs ~1% elective; stabilize with BAE first

— Deflate balloon, position bleeding-side down, intubate with mainstem of nonbleeding lung, emergent CT surgery/IR; high mortality

— Coil or plug embolization by IR; screen all HHT patients with agitated saline contrast echo, then CT chest if positive

CCS pearl: In a massive hemoptysis CCS case, the canonical order set is: NPO, 2 large-bore IVs, type & cross, intubate, ICU admit, reverse anticoagulation, consult pulmonology and interventional radiology, CTA chest, then BAE. Surgery consult runs in parallel as backup.

Bronchial artery embolization (BAE) — the workhorse:

Bronchoscopic interventions (temporizing or definitive for focal lesions):

Surgical resection (lobectomy/pneumonectomy):

PA catheter-induced PA rupture (iatrogenic):

Pulmonary AVM (HHT):

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher pretest probability of malignancy — even minor hemoptysis warrants CT chest and bronchoscopy regardless of CXR

— Polypharmacy: review anticoagulants, antiplatelets, SSRIs (additive bleeding), NSAIDs, bevacizumab, ibrutinib

— Frailty assessment before surgical consideration — BAE often preferred over resection

— Anemia tolerance lower → earlier transfusion threshold in symptomatic cardiac disease (Hb <8)

— Aspiration risk during active bleeding higher; lower threshold to intubate

— Uremic platelet dysfunction worsens bleeding — treat with desmopressin (DDAVP) 0.3 mcg/kg IV, dialysis, cryoprecipitate if severe

— Avoid or minimize iodinated contrast — use lowest-volume CTA protocol; pre/post-hydration; consider MRI angiography if not actively bleeding (rarely practical in massive)

— Renally adjusted dosing of TXA, antibiotics (vancomycin, aminoglycosides), antifungals; voriconazole IV vehicle (cyclodextrin) is nephrotoxic — use oral when possible if GFR <50

— Watch for dialysis-related anticoagulation (heparin in circuit) as a contributor

— Coagulopathy is rebalanced, not simply "bleeder" — INR poorly reflects true bleeding risk; thromboelastography (TEG/ROTEM) more informative when available

— Thrombocytopenia from splenic sequestration — transfuse platelets to >50K for procedures

— Hepatopulmonary syndrome and portopulmonary HTN may complicate oxygenation and hemodynamics

— Avoid hepatotoxic regimens (e.g., RIPE) without close LFT monitoring; isoniazid + rifampin + pyrazinamide all hepatotoxic

Step 3 management: In any elderly smoker with new hemoptysis, even a single episode with a normal CXR, the standard of care is outpatient low-dose CT chest plus pulmonology referral within 1–2 weeks — not reassurance.

Elderly patients:

Chronic kidney disease (CKD):

Hepatic impairment / cirrhosis:

Patients with both CKD and pulmonary-renal syndrome need simultaneous renal and pulmonary management — early nephrology consult is essential.

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Mitral stenosis decompensates in pregnancy (increased volume, HR) → hemoptysis from pulmonary venous hypertension; echo early

— Choriocarcinoma can present with hemoptysis from pulmonary metastases — check β-hCG in any pregnancy-associated or postpartum hemoptysis with abnormal imaging

— PE risk markedly elevated; D-dimer less specific — use CT pulmonary angiography (preferred) or V/Q (lower fetal dose to breast tissue, slightly higher fetal dose) per local protocol

— Imaging principle: maternal benefit outweighs fetal risk in suspected massive bleeding or PE; shield abdomen

— Medications: avoid warfarin, ACE inhibitors, fluoroquinolones, tetracyclines, RIPE pyrazinamide (controversial in US); LMWH preferred anticoagulant if needed

— Foreign body aspiration is a top differential in toddlers — sudden onset, choking history, unilateral wheeze; rigid bronchoscopy diagnostic and therapeutic

— Cystic fibrosis is the leading cause of recurrent hemoptysis in older children/adolescents

— Heiner syndrome (cow's milk protein hypersensitivity) — rare but classic pediatric pulmonary hemosiderosis

— Idiopathic pulmonary hemosiderosis — recurrent DAH, iron-deficiency anemia, no autoimmunity

— Congenital: pulmonary AVM, sequestration, bronchogenic cyst

— Broaden infectious differential: PCP, CMV, invasive aspergillosis, Kaposi sarcoma, atypical mycobacteria

— Galactomannan, β-D-glucan, CMV PCR early

— Lower threshold for early bronchoscopy with BAL

Board pearl: Postpartum woman with hemoptysis + cannonball pulmonary nodules + elevated β-hCG = gestational choriocarcinoma with pulmonary metastases — highly curable with chemotherapy (EMA-CO).

Pregnancy:

Pediatrics:

Immunocompromised hosts (HIV, transplant, chemo):

Sickle cell disease: acute chest syndrome can include hemoptysis; manage with exchange transfusion, antibiotics, supportive care.

Catamenial hemoptysis: cyclical with menses → thoracic endometriosis; diagnosis with cycle-timed CT; treat with hormonal suppression or surgery.

Complications and Adverse Outcomes

— Asphyxiation — leading cause of death in massive hemoptysis; alveolar flooding impairs gas exchange before circulatory collapse

— Aspiration into contralateral lung — extends injury, causes ARDS-like picture; positioning bleeding-side down mitigates

— Hypoxemic respiratory failure requiring intubation and mechanical ventilation

— Hemorrhagic shock — less common but possible with bronchial artery rupture or AV malformation

— Cardiac arrest — usually PEA from hypoxia or hypovolemia

— BAE: spinal cord ischemia (anterior spinal artery), bronchial wall necrosis, dissection, contrast nephropathy, access-site hematoma, post-embolization syndrome (fever, chest pain, leukocytosis)

— Bronchoscopy: airway trauma, worsened bleeding, hypoxemia, sedation complications

— Surgical resection: bronchopleural fistula, empyema, prolonged air leak, post-pneumonectomy syndrome, mortality 5–25% in emergent settings

— Recurrent hemoptysis — 10–30% post-BAE at 1 year; up to 50% in aspergilloma

— Iron deficiency anemia from recurrent or chronic alveolar hemorrhage

— Post-DAH pulmonary fibrosis — restrictive lung disease in survivors of recurrent DAH

— Bronchiectasis as both cause and consequence (post-infectious, post-hemorrhagic)

— PTSD and anxiety — patients who survive massive hemoptysis often have significant psychological sequelae

— Immunosuppression for vasculitis: infection, malignancy, osteoporosis, diabetes (steroids); hemorrhagic cystitis (cyclophosphamide)

— Anticoagulation reversal complications: thrombosis (especially with PCC and andexanet), heparin-induced thrombocytopenia history

Key distinction: A patient who survives the index bleed is not "out of the woods" — rebleeding within 30 days drives readmission and mortality; structured outpatient follow-up within 1–2 weeks is mandatory and frequently tested as a Step 3 transition-of-care item.

Acute complications during the bleeding event:

Procedure-related complications:

Subacute and chronic sequelae:

Treatment-related complications:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Estimated bleeding >100 mL/h or >200 mL in a single episode

— Hemodynamic instability (SBP <90, MAP <65, lactate elevation)

— Hypoxemia (SpO₂ <90% on supplemental O₂) or rising work of breathing

— Airway compromise requiring intubation, or anticipated intubation

— Comorbid cardiopulmonary disease with low physiologic reserve

— Anticoagulation that cannot be rapidly reversed

— Moderate hemoptysis (30–100 mL) that has stabilized

— Recent bleed, normal vitals, but pending workup (CT, bronchoscopy, BAE planning)

— Comorbidities that need monitoring (CHF, COPD, anticoagulation transition)

— Stable, small-volume hemoptysis with identified treatable cause (pneumonia, bronchitis flare)

— Awaiting outpatient-feasible workup that cannot be safely done as an outpatient

— Volume <30 mL/day and trending down

— Hemodynamically stable, normal SpO₂

— No anticoagulation, no severe comorbidities

— Reliable follow-up and return precautions understood

— CT chest and pulmonology follow-up arranged within 1–2 weeks

— Pulmonology — bronchoscopy and diagnostic strategy

— Interventional radiology — BAE planning; call BEFORE bleeding becomes unstable

— Thoracic surgery — backup for BAE failure or resectable focal disease

— Rheumatology/nephrology if pulmonary-renal syndrome suspected

— Hematology for complex coagulopathy reversal

— Infectious disease for TB, invasive fungal, immunocompromised hosts

CCS pearl: In massive hemoptysis CCS cases, simultaneously consulting pulmonology, IR, and thoracic surgery early (before the patient destabilizes) is scored favorably — late escalation when the patient is crashing loses points and lives.

Immediate ICU admission criteria:

Step-down or telemetry admission:

Floor admission:

Outpatient management acceptable when ALL of the following are true:

Consultations to obtain early:

Key Differentials — Same-Category (Pulmonary) Causes

— Acute bronchitis — most common cause of mild blood-streaked sputum in outpatients

— Bacterial pneumonia — especially necrotizing (Klebsiella, S. aureus, anaerobes)

— Tuberculosis — cavitary disease, Rasmussen aneurysm in cavity wall; consider in immigrants, HIV, prison, homeless

— Lung abscess — putrid sputum + blood, air-fluid level on imaging

— Mycetoma/aspergilloma — fungus ball in pre-existing cavity (often old TB); air crescent sign; recurrent hemoptysis often massive

— Septic pulmonary emboli — endocarditis (right-sided, IV drug use), multiple peripheral nodules with cavitation

— Bronchogenic carcinoma — especially squamous cell (central, cavitating) and small cell (central, bulky)

— Carcinoid tumor — young patients, central airway, vascular tumor → recurrent hemoptysis

— Metastatic disease — renal cell, breast, melanoma, choriocarcinoma, sarcoma

— Kaposi sarcoma in HIV/AIDS

— Bronchiectasis — chronic productive cough, recurrent infections, recurrent hemoptysis; high-resolution CT diagnostic

— Cystic fibrosis — bronchiectasis variant; hemoptysis worsens with age

— Foreign body — especially pediatric

— Pulmonary embolism with infarction — pleuritic pain, hemoptysis, dyspnea

— Pulmonary AVM (HHT) — paradoxical embolism, hypoxemia

— Rasmussen aneurysm — pulmonary artery aneurysm in TB cavity

— Pulmonary artery rupture (iatrogenic from PA catheter)

— GPA, MPA, EGPA, anti-GBM (Goodpasture), SLE, antiphospholipid syndrome

— Idiopathic pulmonary hemosiderosis (pediatric)

— Cocaine/crack lung, drug-induced (amiodarone, nitrofurantoin)

Key distinction: Aspergilloma vs invasive aspergillosis — aspergilloma is a saprophytic ball in a pre-existing cavity in an immunocompetent host treated with surgical resection ± antifungals; invasive aspergillosis occurs in immunocompromised hosts and is treated with voriconazole.

Infectious (most common globally):

Neoplastic:

Airway structural disease:

Vascular:

Parenchymal/immune (cause DAH):

Key Differentials — Other-Category Causes (Extrapulmonary and Mimics)

— Mitral stenosis — pulmonary venous hypertension → rupture of bronchial-pulmonary venous anastomoses; classic in rheumatic heart disease, pregnant women, immigrants

— Left ventricular failure / pulmonary edema — pink frothy sputum, not true hemoptysis but commonly confused

— Aortobronchial fistula — rare; prior thoracic aortic surgery, aortic aneurysm; catastrophic, often fatal

— Eisenmenger syndrome — chronic shunt physiology with friable pulmonary vessels

— Thrombocytopenia (ITP, TTP, DIC, leukemia, chemotherapy)

— Coagulopathy — warfarin, DOACs, hemophilia, vitamin K deficiency, liver failure

— Antiplatelet effects — aspirin, P2Y12 inhibitors, dual antiplatelet therapy

— Cocaine ("crack lung") — DAH, eosinophilic pneumonitis

— Anticoagulants and antiplatelets — unmask underlying lesion

— Bevacizumab (anti-VEGF) — significant hemoptysis risk in squamous cell lung cancer (contraindicated)

— Ibrutinib, lenvatinib, sorafenib — bleeding tendency

— Amiodarone, nitrofurantoin, methotrexate — pulmonary toxicity with possible DAH

— Penicillamine, propylthiouracil, hydralazine — drug-induced ANCA vasculitis

— Epistaxis dripping posteriorly, especially in HHT

— Hematemesis — coffee grounds, acidic, food debris, history of GI disease

— Oropharyngeal bleeding — gingivitis, dental, pharyngeal lesions

— Serratia marcescens colonization of sputum — red pigment mimicking blood (classic boards trivia)

Board pearl: A patient with massive hemoptysis after thoracic endovascular aortic repair (TEVAR) or aortic graft has an aortobronchial fistula until proven otherwise — emergent CTA aorta and vascular surgery consult, not bronchoscopy first.

Cardiac causes:

Hematologic and systemic:

Drug- and toxin-induced:

Mimics (pseudohemoptysis):

Trauma: blunt chest trauma with pulmonary contusion; penetrating injury; tracheobronchial rupture.

Secondary Prevention and Long-Term Plan

— Bronchiectasis/CF: daily airway clearance (flutter valve, vest), chronic macrolide (azithromycin 3×/week) for frequent exacerbations, inhaled tobramycin for Pseudomonas colonization, CFTR modulators (elexacaftor/tezacaftor/ivacaftor) for eligible CF patients

— Tuberculosis: full DOT-supervised RIPE regimen; monthly LFTs; document sputum conversion

— Lung cancer: multidisciplinary oncology care; smoking cessation mandatory; consider palliative BAE for recurrent hemoptysis

— Vasculitis (GPA, MPA): maintenance with rituximab or azathioprine/methotrexate after induction; PJP prophylaxis (TMP-SMX); osteoporosis prophylaxis (calcium, vitamin D, bisphosphonate)

— HHT/AVM: annual screening, repeat embolization for recurrence, genetic counseling for family

— Mitral stenosis: percutaneous balloon valvuloplasty or surgical replacement; anticoagulation for AF

— Resumption timing is individualized — weigh underlying indication (mechanical valve, recent PE, AF with high CHA₂DS₂-VASc) against rebleeding risk

— Most patients can resume within 3–7 days after definitive bleeding control if indication is strong; some delay to 2–4 weeks

— Switch from DAPT to single antiplatelet when feasible; consider shorter DAPT duration post-PCI

— Document shared decision-making about resumption

— Combination pharmacotherapy: varenicline or nicotine replacement + bupropion, plus behavioral support

— Address at every visit; document quit date

— Annual influenza, pneumococcal (PCV20 or PCV15→PPSV23), COVID-19 boosters, RSV in eligible adults, pertussis (Tdap)

— Critical in bronchiectasis, CF, COPD, immunosuppressed vasculitis patients

Step 3 management: Post-hemoptysis discharge medication reconciliation should include explicit documentation of anticoagulation hold/resume plan, smoking cessation prescription, vaccination status, and follow-up appointments with PCP and pulmonology within 1–2 weeks — a frequently tested transition-of-care competency.

Etiology-specific long-term management:

Anticoagulation/antiplatelet decisions post-event:

Smoking cessation — universal:

Vaccinations:

Follow-Up, Monitoring, and Rehab/Counseling

— Within 1–2 weeks post-discharge: PCP visit — reconcile medications, review symptoms, check CBC for ongoing anemia

— Within 2–4 weeks: Pulmonology — confirm diagnostic workup completion, review imaging/bronchoscopy, plan ongoing management

— 3 months: Repeat imaging (CT chest) to assess resolution of infiltrate/lesion or completion of cancer staging

— Long-term: disease-specific intervals

— Vasculitis on immunosuppression: monthly CBC, BMP, LFTs initially; ANCA titers may guide relapse monitoring; UA for recurrent renal involvement

— TB: monthly LFTs, visual acuity (ethambutol), sputum AFB monthly until conversion

— Bronchiectasis/CF: spirometry every 3–6 months, sputum cultures for resistant organisms, weight/BMI

— Lung cancer: per oncology surveillance protocol

— Anticoagulation: INR weekly initially if on warfarin; anti-Xa for LMWH in renal impairment; bleeding screen

— Indicated for chronic obstructive disease, bronchiectasis, post-resection patients, ILD

— Improves exercise tolerance, quality of life, reduces readmissions

— Return precautions: any recurrent hemoptysis >1 tablespoon, dyspnea, chest pain, syncope → ED immediately

— Smoking cessation at every encounter

— Medication adherence — particularly anti-TB, immunosuppressants, anticoagulants

— Vaccination updates

— Pulmonary AVM patients: avoid SCUBA diving; antibiotic prophylaxis for dental procedures (paradoxical embolism risk)

Board pearl: In HHT (Osler-Weber-Rendu), lifelong screening of first-degree relatives with contrast echocardiography for pulmonary AVMs and brain MRI for cerebral AVMs is standard — a frequently tested longitudinal management item.

Structured outpatient follow-up timeline:

Monitoring parameters by etiology:

Pulmonary rehabilitation:

Counseling priorities:

Mental health screening: PTSD/anxiety screening in survivors of massive hemoptysis; refer for therapy as needed.

Advance care planning: for advanced lung cancer, end-stage COPD/CF, or recurrent uncontrollable hemoptysis — discuss goals, palliative options, hospice eligibility.

Ethical, Legal, and Patient Safety Considerations

— Massive hemoptysis often presents with impaired decision-making capacity due to hypoxemia or impending intubation

— Use emergency exception (implied consent) for life-saving interventions when no surrogate is available

— When time permits, obtain consent for bronchoscopy, BAE, transfusion, and possible surgery simultaneously to avoid repeated consent interruptions

— Document risk discussion including spinal cord ischemia for BAE, transfusion risks, and possibility of progression to surgery

— Active tuberculosis — reportable to state/local public health in all 50 states; initiate respiratory isolation (negative pressure, N95) before confirmation when suspicion is high

— Public health collaboration for contact tracing

— Occupational exposures (silicosis, asbestos) may require workers' comp reporting

— Anticoagulation hold/resume errors are the most common preventable harm after hemoptysis admission

— Use a structured discharge checklist: explicit hold/resume dates, who is responsible (PCP vs specialist), and follow-up appointment scheduled before discharge

— Medication reconciliation at every transition; bridge therapy plans documented

— Closed-loop communication: confirm pulmonology and IR follow-up appointments are booked and patient has contact information

— Recurrent massive hemoptysis in advanced lung cancer — discuss palliative BAE, radiation, and hospice

— Terminal hemoptysis (catastrophic exsanguinating bleed): dark towels (visual masking), benzodiazepines and opioids for distress, family presence, prepared comfort plan

— Time-out for BAE; mark laterality on bronchoscopy

— Contrast allergy and renal function review before CTA and BAE

— Verify blood products and reversal agents are available before procedure

— TB, bronchiectasis, and untreated CF disproportionately affect underserved populations; ensure access to specialty referral and follow-up

Step 3 management: Before discharge after a hemoptysis admission, perform an explicit "anticoagulation safety check": indication, hold/resume date, who reassesses, and patient counseling on bleeding signs — failure to document this is a common quality and exam-tested transition-of-care error.

Informed consent in emergencies:

Mandatory reporting:

Transitions of care — high-risk window:

Goals of care and palliation:

Patient safety in procedural care:

Equity considerations:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: Recurrent hemoptysis with normal CXR in a smoker is never benign — proceed to CT chest and bronchoscopy; early central airway tumors (carcinoid, squamous cell in situ) routinely have a normal CXR.

Hemoptysis + hematuria + RBC casts → pulmonary-renal syndrome (anti-GBM, GPA, MPA, lupus)

Hemoptysis + saddle nose + sinus disease + c-ANCA/PR3 → granulomatosis with polyangiitis (GPA)

Hemoptysis + asthma + eosinophilia + mononeuritis multiplex → eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss)

Hemoptysis + young smoker + RBC casts + anti-GBM antibody → Goodpasture syndrome (often anti-GBM specifically when limited to lung-kidney)

Hemoptysis + cavitary lung lesion + endemic exposure/HIV → TB

Hemoptysis + "air crescent sign" in old cavity → aspergilloma

Hemoptysis + diastolic rumble + opening snap → mitral stenosis

Hemoptysis + telangiectasias on lips/tongue + epistaxis + family history → HHT (Osler-Weber-Rendu) with pulmonary AVM

Hemoptysis + central bronchial mass + young nonsmoker → bronchial carcinoid

Hemoptysis + cannonball metastases + postpartum + elevated β-hCG → gestational choriocarcinoma

Hemoptysis + DVT/PE risk factors + pleuritic pain → PE with pulmonary infarction

Hemoptysis + recent PA catheter → PA rupture/pseudoaneurysm

Hemoptysis + cyclical with menses → catamenial hemoptysis (thoracic endometriosis)

Hemoptysis + crack cocaine use → DAH/"crack lung"

Hemoptysis + bronchiectasis on HRCT + chronic productive cough → bronchiectasis (CF, post-infectious, primary ciliary dyskinesia)

Massive hemoptysis death mechanism → asphyxiation, not exsanguination

First definitive intervention for massive hemoptysis → bronchial artery embolization

Bronchial arteries supply 90% of massive bleeds → arise from descending aorta (systemic pressure)

Position bleeding-side DOWN → protects the good lung

BAE major complication → spinal cord ischemia

Bevacizumab contraindication → squamous cell lung cancer (hemoptysis risk)

Nebulized TXA dose → 500 mg in 5 mL saline TID-QID

Smoker >40 with single episode of hemoptysis → CT chest + bronchoscopy regardless of CXR

Board Question Stem Patterns

— 58-year-old, 40 pack-years, single 2-tablespoon episode of bright red hemoptysis, normal CXR. Next step?

— Answer: CT chest (low-dose or with contrast) and pulmonology referral for bronchoscopy. Trap: "reassure and follow-up in 6 months."

— Patient coughing up >300 mL, hypoxic, lateral decubitus position. Next step?

— Answer: Intubate with large-bore ETT, position bleeding-side down, ICU, reverse anticoagulation, urgent BAE. Trap: emergent surgery as first option.

— Young adult with hemoptysis, hematuria, RBC casts, elevated creatinine, hemoglobin dropping.

— Answer: Check ANCA and anti-GBM; start pulse methylprednisolone; plasmapheresis if anti-GBM positive; renal biopsy. Trap: waiting for lung biopsy first.

— Immigrant from endemic region, cavitary upper-lobe lesion, recurrent hemoptysis.

— Answer: TB workup with AFB smear/NAAT, respiratory isolation, BAE if massive bleed, RIPE therapy.

— Recurrent epistaxis, lip telangiectasias, hemoptysis, hypoxemia, family history.

— Answer: Contrast echo to screen for pulmonary AVM → CT chest → embolization.

— Recent pregnancy, hemoptysis, cannonball pulmonary nodules.

— Answer: β-hCG, then chemotherapy for choriocarcinoma.

— Pregnant immigrant with dyspnea, hemoptysis, opening snap.

— Answer: Echocardiogram → balloon valvuloplasty.

— ICU patient with Swan-Ganz catheter, sudden massive hemoptysis.

— Answer: Deflate balloon, position bleeding-side down, intubate nonbleeding lung, emergent CT surgery/IR.

— Old TB cavity, recurrent hemoptysis, "air crescent sign."

— Answer: Surgical resection ± antifungal; BAE for acute control.

— Stable patient discharged after hemoptysis admission — what is essential?

— Answer: Documented anticoagulation hold/resume plan, pulmonology follow-up within 2 weeks, smoking cessation, return precautions.

Key distinction: Step 3 stems frequently test the next ambulatory step (CT, referral, follow-up cadence) rather than just acute management — read the question stem for "next best step in management" and consider the outpatient pathway.

Stem 1 — "The smoker with one episode":

Stem 2 — "The massive bleeder":

Stem 3 — "The pulmonary-renal syndrome":

Stem 4 — "The Rasmussen":

Stem 5 — "The HHT family":

Stem 6 — "The postpartum metastases":

Stem 7 — "The mitral stenosis":

Stem 8 — "The PA catheter":

Stem 9 — "The aspergilloma":

Stem 10 — "The transitions of care":

One-Line Recap

Rapid recap bullets:

Step 3 management: When in doubt on a board question, the ambulatory next step for hemoptysis is almost always CT chest plus pulmonology referral — and for inpatient massive bleeding, the canonical CCS order set is airway → reverse coagulopathy → CTA → bronchial artery embolization → surgery as backup.

The teaching point: Hemoptysis management is a two-track problem — massive hemoptysis is an airway emergency managed with positioning, intubation, anticoagulation reversal, and bronchial artery embolization, while nonmassive hemoptysis is a diagnostic problem that, in any smoker over 40 or patient with persistent symptoms, mandates CT chest plus bronchoscopy regardless of CXR findings.

Asphyxiation, not exsanguination, kills in massive hemoptysis — airway protection and bleeding-side-down positioning come before everything else; bronchial arteries (systemic pressure) cause 90% of massive bleeds.

BAE is first-line definitive therapy for massive hemoptysis (85–95% success); surgery is reserved for BAE failure or focal resectable disease; spinal cord ischemia is the dreaded BAE complication.

Pulmonary-renal syndrome (hemoptysis + hematuria + RBC casts) demands immediate ANCA/anti-GBM testing and empiric pulse steroids — do not wait for tissue diagnosis before initiating therapy in severe disease.

Outpatient evaluation requirement: even a single episode of hemoptysis in a smoker over 40, or any patient with recurrent symptoms, requires CT chest and pulmonology referral within 1–2 weeks — a normal CXR never rules out malignancy or significant pathology.

Transitions of care: discharge after any hemoptysis admission must include explicit anticoagulation hold/resume documentation, smoking cessation prescription, vaccination update, return precautions, and confirmed follow-up appointments with PCP and pulmonology.